Home > Insider Trading > Filing (0001735276-23-000033)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1178670	Alnylam Pharmaceuticals Inc.	ALNY	Pharmaceutical Preparations (2834)	770602661

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1829252	Pushkal Garg	675 West Kendall Street Henri A. Termeer Square Cambridge MA 02142	Cmo & Evp Dev & Med Affairs	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-03-03	2,500	$96.45	19,917	No	4	M	Direct
Common Stock	Acquisiton	2023-03-03	2,500	$96.45	22,417	No	4	M	Direct
Common Stock	Disposition	2023-03-03	18,072	$200.00	4,345	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Performance Stock Option 2014 (right to buy)	Disposition	2023-03-03	2,500	$0.00	2,500	$96.45
Common Stock	Stock Option (right to buy)	Disposition	2023-03-03	2,500	$0.00	2,500	$96.45

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2018-08-11	2024-12-17	No	4	M	Direct
0		2024-12-17	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	431	Indirect	by Managed Account
Common Stock	250	Indirect	by Trust

Footnotes

All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2022.
Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
Represents shares held in trust, of which the reporting persons spouse is co-trustee. The reporting person disclaims beneficial ownership of these shares, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
The stock option vested as to 25% of the shares on the first anniversary of the grant date and as to an additional 6.25% of the shares at the end of each successive three month period thereafter until the fourth anniversary of the grant date, and were fully vested on December 17, 2018.